adalimumab-adbm (Cyltezo) vs infliximab-qbtx (Ixifi)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT02871635 · Phase 3 · completed

This was a randomized, double-blind trial against the reference adalimumab product, with a validated Crohn's disease activity score as the primary endpoint. Clinical response at week 4 was similar in both groups (risk ratio 0.945, 90% CI 0.870 to 1.028), within the prespecified non-inferiority margin, and 147 people were randomized against a planned 130.

Hanauer et al. (Lancet Gastroenterol Hepatol, 2021; PMID 34388360) report different figures for this outcome, clinical response in 61 of 68 patients (90%) with BI 695501 and 68 of 72 (94%) with the reference product, because the registry figures are model-based least-squares means.

Reported efficacy

Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). (met)

Result source: NCT02871635

infliximab-qbtx (Ixifi)

Marketed by Pfizer

Approved in Crohn's Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)infliximab-qbtx (Ixifi)
Clinical remission (induction)—Not reported—Not reported
Endoscopic response (induction)—Not reported—Not reported
Clinical remission (maintenance)68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635—Not reported
Endoscopic response (maintenance)—Not reported—Not reported

Clinical remission (induction)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

Endoscopic response (induction)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

Clinical remission (maintenance)

adalimumab-adbm (Cyltezo)
68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635
infliximab-qbtx (Ixifi)
—Not reported

Endoscopic response (maintenance)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

infliximab-qbtx (Ixifi): no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 4 of 4 rows · infliximab-qbtx (Ixifi): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-adbm (Cyltezo)
Dropout rate
25%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Discontinued due to AEs
5.6%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Serious AEs
—BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
8.3%BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
2.8%BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Most frequent reported AEs
arthralgia 8.3%
respiratory tract infection 6.9%
crohn's disease 5.6%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
nasopharyngitis 6.9%
weight increased 4.2%
arthralgia 2.8%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-adbm (Cyltezo)

CDAI ≥ 70 88% (n=68) vs 93.1% (n=72) Humira EU @ 4wk
responder rate · % of participants
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
87.4% (n=68) vs 87.4% (n=72) Humira EU @ 24wk
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Clinical Remission 68.6% (n=68) vs 76.2% (n=72) Humira EU @ 24wk
responder rate · % of participants
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Psoriasismonoclonal antibody
Weak signal

NCT03210259 · Phase 3 · completed

After a 14-week Humira run-in, 238 patients were randomized to switch between Cyltezo and Humira or continue Humira in a double-blind active-controlled period. Both primary pharmacokinetic comparisons met the prespecified equivalence range, but these were drug-level measures rather than direct clinical psoriasis outcomes, so the evidence is moderate. Its registered primary outcomes are pharmacokinetic measures with no comparison, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

infliximab-qbtx (Ixifi)

Marketed by Pfizer

Approved in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)infliximab-qbtx (Ixifi)
PASI 75—Not reported—Not reported
PASI 90—Not reported—Not reported
PASI 100—Not reported—Not reported
sPGA 0/1—Not reported—Not reported
DLQI, change—Not reported—Not reported

PASI 75

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

PASI 90

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

PASI 100

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

sPGA 0/1

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

DLQI, change

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): registry results are on file for Psoriasis, but their comparison mappings are not yet available.

infliximab-qbtx (Ixifi): no structured comparison results are available for Psoriasis.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02137226 · Phase 3 · completed

The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.

No aligned efficacy figure on record for this race.

infliximab-qbtx (Ixifi)

Marketed by Pfizer

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02222493 · Phase 3 · completed

This was a randomized, quadruple-blinded, active-controlled Phase 3 equivalence trial in 650 adults with rheumatoid arthritis taking methotrexate, comparing PF-06438179 with infliximab. The primary endpoint was ACR20 response at Week 14, a clinical disease-activity measure: 61.1% with PF-06438179 versus 63.5% with infliximab, and the reported 95% confidence interval for the difference (-9.92 to 5.11) met the equivalence criterion, indicating no meaningful difference between treatments. This is strong evidence from a well-powered, blinded, controlled trial with a hard clinical endpoint and a met primary comparison.

Reported efficacy

Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%) (met)

Result source: NCT02222493

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)infliximab-qbtx (Ixifi)
ACR20—Not reported61.1% vs 63.5%vs Infliximab-EU Remicade (INX)wk 14 · n 324NCT02222493
12 other results
  • 71.1% vs 64.3% wk 54 · n 280 · Phase 3 · secondary NCT02222493
  • 70.6% vs 64.3% wk 54 · n 143 · Phase 3 · secondary NCT02222493
  • 71.1% vs 68.5% wk 46 · n 280 · Phase 3 · secondary NCT02222493
  • 69.2% vs 68.5% wk 46 · n 143 · Phase 3 · secondary NCT02222493
  • 73.6% vs 70.6% wk 38 · n 280 · Phase 3 · secondary NCT02222493
  • 76.9% vs 70.6% wk 38 · n 143 · Phase 3 · secondary NCT02222493
  • 60.8% vs 64.1% wk 30 · n 324 · Phase 3 · secondary NCT02222493
  • 63.3% vs 65.3% wk 22 · n 324 · Phase 3 · secondary NCT02222493
  • 64.8% vs 65.6% wk 12 · n 324 · Phase 3 · secondary NCT02222493
  • 57.7% vs 61.7% wk 6 · n 324 · Phase 3 · secondary NCT02222493
  • 52.5% vs 58.3% wk 4 · n 324 · Phase 3 · secondary NCT02222493
  • 32.4% vs 37.1% wk 2 · n 324 · Phase 3 · secondary NCT02222493
ACR50—Not reported—Not reported
ACR70—Not reported—Not reported
DAS28-CRP remission—Not reported—Not reported
HAQ-DI, change—Not reported—Not reported
Modified Sharp score, change—Not reported—Not reported

ACR20

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
61.1% vs 63.5%vs Infliximab-EU Remicade (INX)wk 14 · n 324NCT02222493
12 other results
  • 71.1% vs 64.3% wk 54 · n 280 · Phase 3 · secondary NCT02222493
  • 70.6% vs 64.3% wk 54 · n 143 · Phase 3 · secondary NCT02222493
  • 71.1% vs 68.5% wk 46 · n 280 · Phase 3 · secondary NCT02222493
  • 69.2% vs 68.5% wk 46 · n 143 · Phase 3 · secondary NCT02222493
  • 73.6% vs 70.6% wk 38 · n 280 · Phase 3 · secondary NCT02222493
  • 76.9% vs 70.6% wk 38 · n 143 · Phase 3 · secondary NCT02222493
  • 60.8% vs 64.1% wk 30 · n 324 · Phase 3 · secondary NCT02222493
  • 63.3% vs 65.3% wk 22 · n 324 · Phase 3 · secondary NCT02222493
  • 64.8% vs 65.6% wk 12 · n 324 · Phase 3 · secondary NCT02222493
  • 57.7% vs 61.7% wk 6 · n 324 · Phase 3 · secondary NCT02222493
  • 52.5% vs 58.3% wk 4 · n 324 · Phase 3 · secondary NCT02222493
  • 32.4% vs 37.1% wk 2 · n 324 · Phase 3 · secondary NCT02222493

ACR50

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

ACR70

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

DAS28-CRP remission

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

HAQ-DI, change

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

Modified Sharp score, change

adalimumab-adbm (Cyltezo)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 0 of 4 rows · infliximab-qbtx (Ixifi): 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinfliximab-qbtx (Ixifi)
Dropout rate
—Period 1: PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
—Period 2: INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 2: PF-06438179/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/PF-06438179/PF-06438
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06438179/PF-06438179/
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Discontinued due to AEs
—Period 1: PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
—Period 2: INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 2: PF-06438179/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/PF-06438179/PF-06438
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06438179/PF-06438179/
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Serious AEs
5%Period 1: PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
2.8%Period 2: INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
4.6%Period 2: PF-06438179/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
2.4%Period 3: INX/INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
4.8%Period 3: INX/PF-06438179/PF-06438
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
1.2%Period 3: PF-06438179/PF-06438179/
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Most frequent reported AEs
alanine aminotransferase increased 5.9%
infusion related reaction 5.9%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
infusion related reaction 4.2%
alanine aminotransferase increased 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
infusion related reaction 2.9%
alanine aminotransferase increased 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
alanine aminotransferase increased 0%
infusion related reaction 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
alanine aminotransferase increased 0%
infusion related reaction 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
alanine aminotransferase increased 0%
infusion related reaction 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

infliximab-qbtx (Ixifi)

ACR20 61.1% (n=324) vs 63.5% (n=326) Infliximab-EU Remicade (INX) @ 14wk
responder rate · % of participants
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 198 participants as posted
show 12 more results
32.4% (n=324) vs 37.1% (n=326) Infliximab-EU Remicade (INX) @ 2wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 105 participants as posted
52.5% (n=324) vs 58.3% (n=326) Infliximab-EU Remicade (INX) @ 4wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 170 participants as posted
57.7% (n=324) vs 61.7% (n=326) Infliximab-EU Remicade (INX) @ 6wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 187 participants as posted
64.8% (n=324) vs 65.6% (n=326) Infliximab-EU Remicade (INX) @ 12wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 210 participants as posted
63.3% (n=324) vs 65.3% (n=326) Infliximab-EU Remicade (INX) @ 22wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 205 participants as posted
60.8% (n=324) vs 64.1% (n=326) Infliximab-EU Remicade (INX) @ 30wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 197 participants as posted
73.6% (n=280) vs 70.6% (n=143) INX @ 38wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 206 participants as posted
76.9% (n=143) vs 70.6% (n=143) INX @ 38wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 110 participants as posted
71.1% (n=280) vs 68.5% (n=143) INX @ 46wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 199 participants as posted
69.2% (n=143) vs 68.5% (n=143) INX @ 46wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 99 participants as posted
71.1% (n=280) vs 64.3% (n=143) INX @ 54wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 199 participants as posted
70.6% (n=143) vs 64.3% (n=143) INX @ 54wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 101 participants as posted
ACR20 78.7% (n=253) @ 62wk
responder rate · % of participants
No placebo or comparator arm
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 199 participants as posted
show 8 more results
70.6% (n=126) @ 62wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 89 participants as posted
81.7% (n=126) @ 62wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 participants as posted
78.7% (n=253) @ 70wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 199 participants as posted
69% (n=126) @ 70wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 87 participants as posted
77.8% (n=126) @ 70wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 98 participants as posted
75.9% (n=253) @ 78wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 192 participants as posted
68.3% (n=126) @ 78wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 86 participants as posted
77.8% (n=126) @ 78wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 98 participants as posted
ACR50 7.4% (n=324) vs 7.4% (n=326) Infliximab-EU Remicade (INX) @ 2wk
responder rate · % of participants
ACR50 (Week 2)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 24 participants as posted
ACR50 22.2% (n=324) vs 18.1% (n=326) Infliximab-EU Remicade (INX) @ 4wk
responder rate · % of participants
ACR50 (Week 4)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 72 participants as posted
ACR50 27.2% (n=324) vs 24.5% (n=326) Infliximab-EU Remicade (INX) @ 6wk
responder rate · % of participants
ACR50 (Week 6)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 participants as posted
ACR50 29.3% (n=324) vs 31% (n=326) Infliximab-EU Remicade (INX) @ 12wk
responder rate · % of participants
ACR50 (Week 12)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 95 participants as posted
ACR50 35.8% (n=324) vs 33.1% (n=326) Infliximab-EU Remicade (INX) @ 14wk
responder rate · % of participants
ACR50 (Week 14)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 116 participants as posted
ACR50 38.9% (n=324) vs 35.6% (n=326) Infliximab-EU Remicade (INX) @ 22wk
responder rate · % of participants
ACR50 (Week 22)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 126 participants as posted
ACR50 38.6% (n=324) vs 40.5% (n=326) Infliximab-EU Remicade (INX) @ 30wk
responder rate · % of participants
ACR50 (Week 30, pre-dose)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 125 participants as posted
ACR70 1.9% (n=324) vs 1.8% (n=326) Infliximab-EU Remicade (INX) @ 2wk
responder rate · % of participants
ACR70 (Week 2)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 6 participants as posted
ACR70 6.8% (n=324) vs 4% (n=326) Infliximab-EU Remicade (INX) @ 4wk
responder rate · % of participants
ACR70 (Week 4)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 22 participants as posted
ACR70 10.2% (n=324) vs 4.9% (n=326) Infliximab-EU Remicade (INX) @ 6wk
responder rate · % of participants
ACR70 (Week 6)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 33 participants as posted

+ 42 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · infliximab-qbtx (Ixifi)'s landscape